adminの記事一覧

Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.

Am J Med Sci. 333(6): 321-326, 2007.PubMed

Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.

Am J Hypertens. 20(11): 1195-1201, 2007.PubMed

A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure.

Kidney Int. 72(3): 348-358, 2007.PubMed

Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy.

Am J Kidney Dis. 47(3): 439-444, 2006.PubMed

Cigarette smoking affects urinary liver-type fatty acid-binding protein concentration in patients with early diabetic nephropathy.

Diabetes Care. 29(7): 1717, 2006.PubMed

Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis.

Clin Nephrol. 65(1): 1-6, 2006.PubMed

Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria.

Diabetes Metab Res Rev. 22(5): 385-389, 2006.PubMed

Effect of Erythropoietin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Chronic Renal Failure and Anemia.

Am J Nephrol. 26(3): 276-280, 2006.PubMed

Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.

Am J Nephrol. 26(1): 82-86, 2006.PubMed

Liver-type fatty acid-binding protein attenuates renal injury induced by unilateral ureteral obstruction.

Am J Pathol. 169(4): 1107-1117, 2006.PubMed